Metagenomi Therapeutics (MGX) Non-Current Deffered Revenue (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Non-Current Deffered Revenue for 4 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 62.6% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 62.6% YoY), while the FY2025 annual figure was $3.0 million, down 70.8% from the prior year.
• Non-Current Deffered Revenue declined to $1.6 million in Q1 2026 per MGX's latest filing, from $3.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $30.9 million in Q4 2023 and bottomed at $1.6 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $10.6 million across 4 years, with a median of $7.3 million in 2024.
• Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue sank 84.75% — and 2026, when it sank 62.6%.
• Metagenomi Therapeutics' Non-Current Deffered Revenue stood at $30.9 million in 2023, then plunged by 66.9% to $10.2 million in 2024, then slumped by 70.8% to $3.0 million in 2025, then sank by 45.3% to $1.6 million in 2026.
• Business Quant data shows MGX's Non-Current Deffered Revenue at $1.6 million in Q1 2026, $3.0 million in Q4 2025, and $1.9 million in Q3 2025.